focus -WSS

focus

author：explore 2025-09-27 12:56:54 - browse：16

Biogen announced a new round of cost cuts Tuesday, saying that it plans to save $700 million in operating costs and cut 1,000 jobs by 2025.

The company also released second quarter sales and earnings that handily topped the forecasts of Wall Street analysts. In early morning trading, Biogen shares rose more than 1%.

Biogen is attempting to recover from a series of corporate stumbles, the biggest of which involved the development and launch of the Alzheimer’s drug Aduhelm. The medicine was the first of a new class of disease-modifying Alzheimer’s drugs to be approved by the Food and Drug Administration. But doubts about the quality of the data behind the medicine meant that Medicare wouldn’t pay for it and doctors did not prescribe it. The resulting financial disaster cleaned out Biogen’s executive suite.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： The high cost of giving birth even with insurance
Next article： In venture capital firm's success, lessons for turning crisis into profit

WSS

Websites selling Wegovy, Zepbound ingredients targeted by FDA

AMAs digital advisors table RPM coding reform proposal, again

STAT Boddities: What happens to the brain when we get scared?

Why Eli Lilly’s earnings didn’t quite live up to the hype

CDC launches VaccineFinder tool to locate Covid

Astronauts get first look at the spacecraft that will fly them around the moon

hotspot

focus

hotspot

Sports medicine is finally prioritizing gender equality

Travel bans should be based on evidence, not politics or fear

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

Hospitals use virtual reality to design more inclusive rooms for kids

How to save PrEP access — and even expand it

In venture capital firm's success, lessons for turning crisis into profit

The cancer drug shortage isn’t new — and neither are the solutions

Lessons Learned: This is why you network to find that industry job you want

DIEP, the 'gold standard' of breast reconstruction, is under threat

Tome Biosciences co

entertainment

Zapping the brain for stroke rehab: Pivotal clinical trial begins

Websites selling Wegovy, Zepbound ingredients targeted by FDA

Judge schedules Friday hearing on proposed protective order in Jan. 6 case

Artificial intelligence use in health care faces greater scrutiny in 2024

Bernie Sanders gets little from pharma CEOs on drug prices

Ohioans vote in high

focus

focus

focus

entertainment